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Introduction
This document is a summary of the concepts and 
definitions in the revised area. Detailed background 
information about the process of revision can be found in 
two related documents (see footnote 3). The changes are, 
for the most part, related to the theoretical component of 
the indicator. Data collection recommendations will remain 
mostly unchanged, with two exceptions: the addition of 
intensive cannabis use data collection based on general 
population surveys methodology; and making provision for 
interested countries to report on other — including new — 
drugs. However, most of the existing work will correspond 
to a subset of the revised indicator area.
‘Prevalence of problem drug use’ was established as one 
of the five key epidemiological indicators to monitor the 
EU drug situation (EU Council CORDROGUE 67, 2001). 
Its purpose was defined from the beginning as: ‘to provide 
comparable, reliable estimates of the prevalence and 
patterns of more severe drug use’ (EMCDDA Management 
Board, 2001). The importance of and difficulty in finding a 
common definition of ‘problem drug use’ was understood 
from the beginning. In 2004 methodological guidelines 
(1), a pragmatic definition applicable across diverse data 
sources was published: ‘Problem drug use is injecting drug 
use or regular and/or long-term use of opiates (2), cocaine 
and/or amphetamines.’
The work under the indicator area relied predominantly 
on indirect statistical extrapolations from existing data 
sources. These often resulted in estimates of populations 
of heavy, mostly marginalised, opioid users.
The main motives for the revision of the key indicator were:
1. A changing drug situation and the increasing 
importance of knowing the prevalence of new, or newly 
increased in size, groups of users (such as those with 
heavy cannabis use and heavy stimulants use without 
the presence of opioids use, users of new drugs, etc.).
2. Changes in the nature and availability of data sources: 
more detailed information is now often available, which 
makes more specific estimates possible.
3. To establish a conceptual framework, linked with 
operational definitions.
4. To clear up confusion around the area name (including 
unintended labelling).
Additional issues that needed to be addressed are: the 
limited capacity of the content of the current area (i.e. 
available data, methods, etc.) to monitor adequately 
trends over time; and characteristics of the drug users in 
question.
The process of revision involved expert meetings and 
discussions, a first proposal in 2011 (3), an online survey 
in 2012, several bilateral discussions with experts and 
scientists and a finalised proposal at the end of 2012. 
This document, which represents a short summary of 
the revision, will be followed by the implementation of 
all changes into updated indicator guidelines and other 
indicator-defining documents (these can be located 
through http://www.emcdda.europa.eu/themes/key-
indicators/pdu). These guidelines will set a minimum, 
core data set to be reported (which will remain to a 
considerable extent compatible with existing reporting) 
and will allow extra room to report additional data on 
a voluntary basis depending on each National focal 
point’s capacity, resources and type of drug scenario. 
For example, experts are welcome to work on severity 
levels of drug use (e.g. to add several dimensions of more 
frequent or severe drug use) or on more complex concepts 
of polydrug use where combinations of substances are 
understood as a factor to increase risk. (These were just 
two of the topics suggested in discussions related to the 
revision process.)
(1) EMCDDA (2004), Recommended draft technical tools and guidelines key epidemiological indicator: prevalence of problem drug use  
(http://www.emcdda.europa.eu/html.cfm/index65519EN.html).
(2) ‘Opiates’ were later changed to ‘opioids’.
(3) Detailed documents on these steps in the process are available from the EMCDDA: 1. ‘Principles of PDU revision’, February 2012; 2. ‘Problem drug use 
key indicator reconceptualisation/revision 2012: results of an online survey collecting comments on the process from all EMCDDA Member States and some 
independent scientists’, May 2012. These documents also include the discussion on other, alternative concepts that were suggested and discussed in the 
process of revision.
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The PDU indicator (revised): high 
risk drug use
The revised indicator area focuses on ‘high-risk drug 
use’ (HRDU). The term ‘high-risk drug use’ means 
‘recurrent drug use that is causing actual harms (negative 
consequences) to the person (including dependence, but 
also other health, psychological or social problems) or is 
placing the person at a high probability/risk of suffering 
such harms’ (4).
The principal task of this indicator area is to estimate 
annual prevalence of high-risk drug use, or the sizes of 
populations with high-risk drug use. These estimates are 
calculated and reported to the EMCDDA in a standardised 
way (according to existing guidelines on local and national 
prevalence estimation).
At the same time, more emphasis than in the past will be 
put on increasing the ability of the indicator area to report 
on trends in high-risk drug use. This is, however, still a 
developmental area (see below).
Another important task is to give some insight into 
the characteristics of these populations by utilising 
information through collaboration with the Treatment 
demand indicator (TDI), which collects standardised 
data on the characteristics of a broad sample of high-
risk drug users and also data from diverse studies using 
non-treatment data sources (currently reporting the 
results through annual National reports). Incidence of 
this behaviour, estimated in scientific studies, is also a 
useful element to complement the understanding of the 
situation.
Substances included in the monitoring are the most 
harmful and sufficiently prevalent illegal/illicit substances, 
i.e. those that are causing most harm (predominantly to an 
individual user, but also at the population level depending 
on the intensity of harm and prevalence of use). Potentially 
harmful but rarely used (i.e. with low prevalence on the 
national/sub-national level) substances are excluded 
from the monitoring (please refer to the EU Early warning 
system for these).
The studies indirectly estimating the sizes of populations 
with high-risk drug use, which are at the core of the 
indicator, should be planned and conducted bearing in 
mind their utility for informing policy about the need for 
drug treatment (defined in a broad way — see below). It 
is important to explicitly formulate this, because to some 
extent it determines the data sources and case definitions 
that need to be used in prevalence studies.
The drug treatment definition spelled out in the TDI 
protocol (5) (and also EMCDDA Treatment cross-unit 
project) is: ‘Drug treatment is defined as an activity 
(activities) that directly targets people who have problems 
with their drug use and aims at achieving defined aims 
with regard to the alleviation and/or elimination of 
these problems, provided by experienced or accredited 
professionals, in the framework of recognised medical, 
psychological or social assistance practice.’
The conceptual framework translates into a definition, 
further operationalised by drug, which suggests how 
to measure ‘high-risk drug use’: ‘High-risk drug use is 
measured as the use of psychoactive substances (6) by 
high-risk pattern (e.g. intensively) and/or by high-risk 
routes of administration in the last 12 months.’
Note: ‘Intensively’ is further defined by drug under ‘case 
definition’. The main point of these case definitions is to 
filter out experimental and occasional users who have a 
lower risk of harms and are not the core population for the 
assessment of treatment need (7).
Three elements of the final revision proposal are developed 
in the following sections:
A — Estimates of prevalence of high-risk drug use
B — Monitoring of characteristics of high-risk drug users 
and trends
C — Opioid substitution treatment (OST) clients in the 
revised indicator
A — Estimates of prevalence of high-risk 
drug use
A1 — Common estimates
The following estimates are to be derived at national 
— and if possible sub-national (8) — level and reported 
to the EMCDDA by all EMCDDA Member States. Their 
(4) The text in quotation marks can be considered a theoretical or conceptual definition of the area. This broad definition implies appropriate flexibility in 
reporting. Periodic revisions of the area should follow in order to determine if new categories (drugs, patterns of use, specific populations) need to be included 
and reported.
(5) See ‘TDI standard protocol 3.0: guidelines for reporting data on people entering drug treatment in European countries’, EMCDDA, Lisbon, September 2012 
(http://www.emcdda.europa.eu/publications/manuals/tdi-protocol-3.0).
(6) Excluding alcohol, tobacco and caffeine.
(7) Please see the report/technical paper ‘Literature review to support PDU revision’ (to be published in 2013) for more details on the scientific evidence used 
to suggest the present definitions.
(8) See ‘Indirect prevalence estimation guidelines’ for more information (http://www.emcdda.europa.eu/themes/key-indicators/pdu).
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selection is based solely on the current epidemiological 
data, suggesting that they have a significant presence in 
all countries, and is not necessarily related to their level of 
harmfulness.
1. High-risk opioid use (comparable to what was 
previously called ‘problem opioid use’)
1.1 Methods and data sources: Indirect estimates with 
their respective data sources (see indirect methods 
guidelines).
1.2 Case definition at the level of the data source, in order 
of preference:
Recall period: last 12 months.
1.2.1 Use of opioids, including opioid medicines, weekly 
or more frequently for at least six months of the past 12 
months (alternatively can be measured as 26 days or 
more in the past 12 months), not according to medical 
prescription.
OR 
1.2.2 A medical diagnosis according to current DSM or 
ICD criteria, e.g. ‘harmful use or dependence on opioids or 
opioid use disorder’ (diagnosed in the past 12 months) (9).
OR 
1.2.3 Any other best proxy of the above that can be 
collected at the level of the data source.
Note: opioid users who are stabilised on opioid 
substitution treatment (OST) are, if possible, reported 
separately. See section on the handling of OST cases.
2. Injecting drug use
2.1 Methods and data sources: Indirect estimates with 
their respective data sources (see indirect methods 
guidelines).
2.2 Case definition: injecting use of any psychoactive 
substance(s) not according to medical prescription in the 
last 12 months.
Recall period: last 12 months.
OPTIONAL: breakdown by injected substances.
3. Frequent and high-risk cannabis use
Synthetic cannabinoids may also be reported if this is 
possible and relevant for country’s drug situation.
(9) In practice, frequency of use threshold and medical diagnosis might not point to the same cases and another proxy might again select a different set of 
cases. However, they were chosen as wide pragmatic case definitions, most frequently available at the existing data sources of different countries.
(10) However, this does not limit the possibility to use any other methods, including indirect methods, at the national or subnational level.
3.1 Methods and data sources: At present, two separate 
estimates are foreseen, based on general population 
surveys and school surveys (10). 
a) An estimate of the number of daily, or almost daily 
users, in the last 30 days (see case definition 3.2.1). 
b) An estimate of the prevalence of ‘cannabis use 
disorders’. This applies only to countries with sufficient 
cannabis use prevalence and/or sufficient sample size 
in the general population survey and/or school survey 
(guidelines in preparation). It is obtained by means 
of incorporating short cannabis scales in the general 
population surveys (see case definition 3.2.2).
3.2 Case definition at the level of data source: 
Recall periods: last 12 months, last 30 days.
3.2.1 Use of cannabis daily, or almost daily, in the 
preceding 12 months; for general population surveys or 
school surveys this will be approximated by use of 20 or 
more days in the 30 days preceding interview (or similar).
3.2.2 Medical diagnosis according to current DSM or 
ICD criteria, e.g. cannabis harmful use or dependence or 
cannabis use disorder diagnosed in the past 12 months. 
For the purpose of monitoring this phenomenon at the 
level of general population surveys and school surveys, 
this will be approximated by short psychometric scales 
(see the respective upcoming guidelines).
A2 — Country-specific estimates
The following estimates are to be calculated and reported 
to the EMCDDA only in cases where this is relevant for a 
country’s specific drug situation and is feasible:
1. High-risk cocaine use (comparable to what was 
previously called ‘problem cocaine use’)
1.1 Methods and data sources: 
a) Indirect estimation methods with their respective data 
sources (see indirect methods guidelines), new data 
sources to be sought and tested (e.g. emergency room 
visits, probation data, etc.).
b) Alternative methods for more socially integrated parts 
of this population — developmental work in progress with 
the general population surveys experts, other possibilities 
to be explored (e.g. wastewater analysis combined with 
modelling, incorporating information from targeted 
surveys).
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1.2 Case definition at the level of the data source, in order 
of preference:
Recall period: past 12 months
1.2.1 Either of these two conditions justifies the case 
definition:
a) Use of cocaine weekly or more frequently for at least 
six months of the past 12 months (alternatively can be 
measured as 26 days or more in the past 12 months). 
b) Recurrent crack cocaine use.
OR
1.2.2 A medical diagnosis according to current DSM or 
ICD criteria: ‘harmful use or dependence on cocaine or 
stimulant use disorder’.
OR
1.2.3 Any other best proxy of the above that can be 
collected at the level of the data source.
2. High-risk amphetamines use (amphetamine and 
methamphetamine: comparable to what was previously 
called ‘problem amphetamines use’)
2.1 Methods and data sources: 
a) Indirect estimation methods with their respective data 
sources (see indirect methods guidelines), or possibly new 
data sources. 
b) Alternative methods to be explored (e.g. wastewater 
analysis combined with modelling, general population 
surveys, possibly combined with targeted surveys).
2.2 Case definition at the level of the data source, in order 
of preference:
Recall period: past 12 months.
2.2.1 Use of amphetamines weekly or more frequently for 
at least six months of the past 12 months (alternatively 
can be measured as 26 days or more in the past 12 
months).
OR
2.2.2 A medical diagnosis according to current DSM or ICD 
criteria: ‘harmful use or dependence on amphetamines/
other stimulants or stimulants use disorder’.
OR
2.2.3 Any other best proxy of the above that can be 
collected at the level of the data source.
3. High-risk use of other substances
High-risk use of other substances (according to national 
or regional need for the estimates): cathinones, GHB, 
benzodiazepines, volatile substances, other.
This is a broad group of substancec, thus definite case 
definitions cannot be formulated, however as a general 
rule, it is possible to apply a case definition similar to those 
outlined for the previous substances. E.g. at least weekly 
use of a substance for 6 months or more, or a medical 
diagnosis or a nearest proxy of those.
A3 — Elements to understand polydrug use (11)
The following data is to be reported to the EMCDDA 
through national reporting. Only the first element is 
common for all countries; the other two are optional.
1. Overlaps between the above-mentioned groups, 
accounting for polydrug use
The above-mentioned figures by substance are to include 
all users of the drug in question who have the specified 
pattern of use, regardless of whether they use other 
drugs or not. Thus, there will exist overlaps between the 
previously mentioned estimates.
All significant known overlaps (for example, cocaine users 
who also use heroin) should be reported through the 
National reports (see national reporting guidelines). In 
addition, their size should be estimated, where possible.
The estimates of sizes of the overlaps may be derived from 
existing surveys, out-of-treatment studies or treatment 
data, in cases where it is impossible to include them in the 
prevalence estimation study per se.
2. High-risk use of opioids, cocaine and/or amphetamines 
(i.e. total after accounting for overlaps, equivalent to what 
was previously called ‘PDU total’)
Optional.
3. Estimate of polydrug use where breakdown by used 
substances is not available
Optional, and where applicable.
e.g. F19 in ICD-10
In cases where this component is used, there should be a 
reason to believe that the users included in the estimates 
have a high-risk pattern of drug use falling under the 
indicator area, i.e. that the combinations of substances 
do not solely include substances that are not subject to 
EMCDDA monitoring (e.g. alcohol and tobacco).
(11) Polydrug use has been chosen by the EMCDDA as a broader term, including shorter and longer time-periods in which two or more substances have been 
used. Thus it would be broader than terms such as ‘multiple drug use’, ‘concurrent drug use’, etc. and include them.
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B — Monitoring of characteristics of high-
risk drug users and trends
Incidence of high-risk drug use
Studies of incidence of drug use mainly describe a 
possible epidemic curve from a long-term perspective, 
and the current state within it, and thus are very important 
elements in the interpretation of long-term trends and 
service coverage. Possibilities for prediction are limited but 
exist.
A requirement is not foreseen for incidence estimates to 
be constructed and regularly reported by each EMCDDA 
Member State. On the other hand, it is foreseen that 
EMCDDA, with its external contractors, if budget available, 
will assist interested countries in computing these from 
routinely collected data (TDI) periodically.
Characteristics of high-risk drug users and options for 
better understanding of current, possibly new, trends
Besides knowing the prevalence of the phenomenon 
of high-risk drug use, having an insight into the 
characteristics of users (for example, their age distribution, 
gender, other demographic data, drugs used, patterns of 
use, mental/physical health, social and legal problems) 
will be valuable. This is important not only to understand 
the drug situation but, even more so, in order to plan (an 
improvement of) public health interventions.
This component will utilise: (i) data collected within the 
framework of the TDI as this represents best available 
data that can be considered as a broad sample of high-risk 
drug users; and (ii) data/information collected by existing 
studies of data sources other than drug treatment (for 
example, seroprevalence studies, surveys at low threshold 
facilities, street population studies and other studies in 
out-of-treatment settings). 
The EMCDDA is preparing an inventory of larger, and 
sometimes at national level, studies of drug using 
populations sampled from non-treatment data sources, 
more or less regularly conducted in most countries. These 
provide insight not only into the characteristics of HRDUs, 
but also into (new) trends in these groups. 
Moreover, the characteristics of individuals attending 
these two different settings (treatment and out-of-
treatment settings) can be compared, taking into account 
the complexity of the dynamic process of the natural 
history of drug use including treatment entry, times in and 
out of treatment and active and inactive drug use state, 
and so on.
Standard data collection in standard tables (ST) or 
structured questionnaires (SQ) is not foreseen at the 
moment, but national reporting guidelines should be 
enhanced to improve the collection of this existing 
data through the yearly National reports. The ST7 Fonte 
template is expected to include space for references to 
these studies (primarily those in relation to data sources 
used in the regular prevalence estimation).
Other approaches should be tested, for example building 
the information on change directly into all collection and 
estimation procedures (i.e. collecting data from drug users 
on their drug use not only in the last year but also in the 
year before). Waste water analysis can serve as a basis for 
information on community drug use, but research work 
and especially triangulation with other data is necessary to 
have a better idea how to interpret these.
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C — Opioid substitution treatment (OST) 
clients in the revised indicator
The PDU indicator aimed to include all regular and/or 
long-term opioid users, including those on OST, which has 
been implemented in Member State countries to a varying 
extent.
The issue of including OST clients in high-risk drug 
use prevalence estimates has a ‘philosophical’ and 
a methodological dimension. Philosophically, some 
argued that it is not correct from the perspective of 
client motivation and rights to call them ‘problem drug 
users’ if they are stabilised, (almost) abstinent from illicit 
substances and perhaps also socially integrated. On the 
other hand, treatment coverage calculations — which 
include substitution treatment as an important element 
— in general need to have a denominator including OST 
cases.
The methodological dimension becomes problematic only 
if the registry of OST clients — as opposed to solely new 
entries (e.g. in a given year) to OST — is used to calculate 
HRDU prevalence (e.g. in a capture–recapture study). This 
is because of (more serious) violation of homogeneity of 
capture assumption, as long-term stable clients might 
have close to zero probability of appearing in other data 
sources, for example police data. Merging them with 
non-stable clients will thus result in a heterogeneous 
population.
On the other hand, non-stable and/or new OST clients will 
naturally appear in HRDU estimates, even if non-OST data 
sources are used or if entry to OST treatment instead of 
the full OST registry is used.
A solution was sought to overcome the problems of 
violation of homogeneity assumption, and the need for 
treatment coverage calculations. It was thought that, as a 
first step, it would be useful to gain a better understanding 
of the present situation. This should be achieved by adding 
some questions to ST7/Fonte, along these lines:
•	 Is the OST data set used in estimation?
•	 Are OST clients de facto included in the resulting 
opioids estimate, or a part of them included?
•	 If only a part of them is included, what is the definition 
of those included/excluded (this can be on the basis of 
case definition if part of OST data set is used or follow 
from methods and data sources used)?
•	 What is the size of OST population in the country and 
which part of it is included in the high-risk opioid use 
estimate (overlap between OST total and the high-risk 
opioid use estimate)?
As HRDU by definition does not include individuals who 
are on opioid medication used according to a doctor’s 
prescription and do not use other drugs in a high-risk 
way, in the future, data collection and reporting should be 
streamlined and improved in line with this. This means in 
practice that:
1. In cases where the OST registry is used in estimation 
exercise (and not only entries to OST treatment in that 
particular year), a case definition/inclusion criteria are 
needed. This has to be developed in the near future.
2. In order to calculate OST coverage correctly and void 
of the above-mentioned methodological problems 
(violation of the homogeneity assumption), three 
elements (counts) will be needed: opioid HRDUs not 
in OST treatment; opioid HRDUs in OST treatment; 
and stabilised OST clients. It is foreseen that the work 
will be done with the Health and Social Responses 
monitoring team to agree how to best collect these 
data/elements.
3. Some countries report that in their programmes (nearly) 
all OST clients are still HRDUs or that data collection 
following a specific case definition is currently not 
possible while the use of the OST registry in estimation 
is currently unavoidable. There will remain space for 
them to report in the best achievable way. Information 
on the used procedures/case definitions will be 
collected in ST-7.
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